Global Spinal Muscular Atrophy (SMA) Treatment Market Size, Share, Growth, Trends, Company Analysis and Forecast 2019-2026

The global spinal muscular atrophy (SMA) treatment market size is expected to reach USD 4.3 billion by 2026. It is estimated to register a CAGR of 13.7% during the forecast period 2019 to 2026. Due to the rare nature and complexity of these diseases, scientific knowledge pertaining to them is scarce. However, there are various initiatives undertaken to increase awareness regarding rare diseases and to support SMA communities. This is anticipated to boost the market development over the coming years.

Various SMA communities and companies have collaborated for developing disease treatment therapy. For example, RG7916, which is an investigational therapy being developed by Roche in collaboration with SMA Foundation and PTC Therapeutics. Thus, heavy investments in R&D by major companies are also projected to contribute toward the growth of this market. CureSMA, SMA Foundation, and SMA Europe are some of the organizations actively supporting R&D pertaining to SMA.

CureSMA provided funding to a research project to Biogen and Ionis Pharmaceuticals, Inc. for developing Spinraza, which received U.S. FDA approval in 2016. This organization has invested nearly USD 70 million in the research pertaining to SMA, which also included a planned investment of USD 5 million in the coming years.

Key suggestions from the report:

  • The global spinal muscular atrophy treatment market is projected to expand at a CAGR of 12.9% over the forecast period
  • Based on disease type, type 1 accounted for the largest revenue share owing to rising incidence of type 1 SMA
  • By treatment, the drug segment accounted for the largest revenue share in 2017
  • North America will retain its lead as the largest regional market; however Asia Pacific is anticipated to register the fastest CAGR over the forecast period
  • The market is presently led by Biogen Inc. Biogen's Spinraza is the only approved commercialized treatment for SMA, owing to which market is not competitive. However, this trend is expected to change after the commercialization of other treatment therapies post 2020.

Market Segmentation

Based on the Region:

  • Asia-Pacific (China, Japan, South Korea, India and ASEAN)
  • North America (US and Canada)
  • Europe (Germany, France, UK and Italy)
  • Rest of World (Latin America, Middle East & Africa)

Based on the Type:

  • Type I Spinal Muscular Atrophy (SMA)
  • Type II Spinal Muscular Atrophy (SMA)
  • Type III Spinal Muscular Atrophy (SMA)

Based on the Application:

  • Hospitals
  • Ambulatory Surgical Centers
  • Diagnostic Centers
  • Others

Table of Contents

Chapter 1 Research Methodology
                 1.1 Information Procurement
                 1.2 Data Analysis
Chapter 2 Executive Summary
                 2.1 Market Snapshot
Chapter 3 Spinal Muscular Atrophy Treatment Market Variables, Trends & Scope
                 3.1 Market Segmentation & Scope
                 3.2 Market Driver Analysis
                     3.2.1 Rising importance of rare diseases
                     3.2.2 Increasing initiatives for creating awareness of SMA
                     3.2.3 Growing research initiatives by market players for developing treatment for SMA
                 3.3 Market Restraint Analysis
                     3.3.1 Limited access to treatment of SMA
                 3.4 Key Opportunities Prioritized
                 3.5 Spinal Muscular Atrophy Treatment Market - SWOT Analysis, by Factor (Political & legal, Economic, and Technological)
                 3.6 Industry Analysis - Porter’s
Chapter 4 Spinal Muscular Atrophy Treatment Market: Disease Type Estimates & Trend Analysis
                 4.1 Spinal Muscular Atrophy Treatment Market: Disease Type Movement Analysis
                 4.2 Type 1
                     4.2.1 Type 1 market revenue estimates and forecasts, 2015 - 2026 (USD Million)
                 4.3 Type 2
                     4.3.1 Type 2 market revenue estimates and forecasts, 2015 - 2026 (USD Million)
                 4.4 Type 3
                     4.4.1 Type 3 market revenue estimates and forecasts, 2015 - 2026 (USD Million)
                 4.5 Type 4
                     4.5.1 Type 4 market revenue estimates and forecasts, 2015 - 2026 (USD Million)
Chapter 5 Spinal Muscular Atrophy Treatment Market: Treatment Estimates & Trend Analysis
                 5.1 Spinal Muscular Atrophy Treatment Market: Treatment Movement Analysis
                 5.2 Gene Therapy
                     5.2.1 Gene therapy market revenue estimates and forecasts, 2015 - 2026 (USD Million)
                 5.3 Drug
                     5.3.1 Drug market revenue estimates and forecasts, 2015 - 2026 (USD Million)
                     5.3.2 Spinraza
                         5.3.2.1 Spinraza market revenue estimates and forecasts, 2015 - 2026 (USD Million)
                     5.3.3 RG6083 (Olesoxime)
                         5.3.3.1 RG6083 (Olesoxime) market revenue estimates and forecasts, 2015 - 2026 (USD Million)
                     5.3.4 RG7916
                         5.3.4.1 RG7916 market revenue estimates and forecasts, 2015 - 2026 (USD Million)
Chapter 6 Spinal Muscular Atrophy Treatment Market: Route of Administration Estimates & Trend Analysis
                 6.1 Spinal Muscular Atrophy Treatment Market: Route of Administration Movement Analysis
                 6.2 Oral
                     6.2.1 Oral market revenue estimates and forecasts, 2015 - 2026 (USD Million)
                 6.3 Intrathecal
                     6.3.1 Intrathecal revenue market estimates and forecasts, 2015 - 2026 (USD Million)
Chapter 7 Spinal Muscular Atrophy Treatment Market: Regional Estimates & Trend Analysis by Disease Type, Treatment, and Route of Administration
                 7.1 Spinal Muscular Atrophy Treatment Market: Regional Movement Analysis
                 7.2 North America
                     7.2.1 Market estimates and forecasts, by disease type, 2015 - 2026 (USD Million)
                     7.2.2 Market estimates and forecasts, by treatment, 2015 - 2026 (USD Million)
                     7.2.3 Market estimates and forecasts, by, route of administration, 2015 - 2026 (USD Million)
                     7.2.4 U.S.
                         7.2.4.1 Market estimates and forecasts, by disease type, 2015 - 2026 (USD Million)
                         7.2.4.2 Market estimates and forecasts, by treatment, 2015 - 2026 (USD Million)
                         7.2.4.3 Market estimates and forecasts, by route of administration, 2015 - 2026 (USD Million)
                     7.2.5 Canada
                         7.2.5.1 Market estimates and forecasts, by disease type, 2015 - 2026 (USD Million)
                         7.2.5.2 Market estimates and forecasts, by treatment, 2015 - 2026 (USD Million)
                         7.2.5.3 Market estimates and forecasts, by route of administration, 2015 - 2026 (USD Million)
                 7.3 Europe
                     7.3.1 Market estimates and forecasts, by disease type, 2015 - 2026 (USD Million)
                     7.3.2 Market estimates and forecasts, by treatment, 2015 - 2026 (USD Million)
                     7.3.3 Market estimates and forecasts, by route of administration, 2015 - 2026 (USD Million)
                     7.3.4 U.K.
                         7.3.4.1 Market estimates and forecasts, by disease type, 2015 - 2026 (USD Million)
                         7.3.4.2 Market estimates and forecasts, by treatment, 2015 - 2026 (USD Million)
                         7.3.4.3 Market estimates and forecasts, by route of administration, 2015 - 2026 (USD Million)
                     7.3.5 Germany
                         7.3.5.1 Market estimates and forecasts, by disease type, 2015 - 2026 (USD Million)
                         7.3.5.2 Market estimates and forecasts, by treatment, 2015 - 2026 (USD Million)
                         7.3.5.3 Market estimates and forecasts, by route of administration, 2015 - 2026 (USD Million)
                 7.4 Asia Pacific
                     7.4.1 Market estimates and forecasts, by disease type, 2015 - 2026 (USD Million)
                     7.4.2 Market estimates and forecasts, by treatment, 2015 - 2026 (USD Million)
                     7.4.3 Market estimates and forecasts, by route of administration, 2015 - 2026 (USD Million)
                     7.4.4 Japan
                         7.4.4.1 Market estimates and forecasts, by disease type, 2015 - 2026 (USD Million)
                         7.4.4.2 Market estimates and forecasts, by treatment, 2015 - 2026 (USD Million)
                         7.4.4.3 Market estimates and forecasts, by route of administration, 2015 - 2026 (USD Million)
                     7.4.5 China
                         7.4.5.1 Market estimates and forecasts, by disease type, 2015 - 2026 (USD Million)
                         7.4.5.2 Market estimates and forecasts, by treatment, 2015 - 2026 (USD Million)
                         7.4.5.3 Market estimates and forecasts, by route of administration, 2015 - 2026 (USD Million)
                 7.5 Latin America
                     7.5.1 Market estimates and forecasts, by disease type, 2015 - 2026 (USD Million)
                     7.5.2 Market estimates and forecasts, by treatment, 2015 - 2026 (USD Million)
                     7.5.3 Market estimates and forecasts, by route of administration, 2015 - 2026 (USD Million)
                     7.5.4 Mexico
                         7.5.4.1 Market estimates and forecasts, by disease type, 2015 - 2026 (USD Million)
                         7.5.4.2 Market estimates and forecasts, by treatment, 2015 - 2026 (USD Million)
                         7.5.4.3 Market estimates and forecasts, by route of administration, 2015 - 2026 (USD Million)
                     7.5.5 Brazil
                         7.5.5.1 Market estimates and forecasts, by disease type, 2015 - 2026 (USD Million)
                         7.5.5.2 Market estimates and forecasts, by treatment, 2015 - 2026 (USD Million)
                         7.5.5.3 Market estimates and forecasts, by route of administration, 2015 - 2026 (USD Million)
                 7.6 Middle East and Africa (MEA)
                     7.6.1 Market estimates and forecasts, by disease type, 2015 - 2026 (USD Million)
                     7.6.2 Market estimates and forecasts, by treatment, 2015 - 2026 (USD Million)
                     7.6.3 Market estimates and forecasts, by route of administration, 2015 - 2026 (USD Million)
                     7.6.4 South Africa
                         7.6.4.1 Market estimates and forecasts, by disease type, 2015 - 2026 (USD Million)
                         7.6.4.2 Market estimates and forecasts, by treatment, 2015 - 2026 (USD Million)
                         7.6.4.3 Market estimates and forecasts, by route of administration, 2015 - 2026 (USD Million)
Chapter 8 Competitive Landscape
                 8.1 Biogen
                     8.1.1 Company overview
                     8.1.2 Financial performance
                     8.1.3 Product benchmarking
                     8.1.4 Strategic initiatives
                 8.2 Ionis Pharmaceuticals, Inc.
                     8.2.1 Company overview
                     8.2.2 Financial performance
                     8.2.3 Product benchmarking
                     8.2.4 Strategic initiatives
                 8.3 F. Hoffmann - La Roche Ltd
                     8.3.1 Company overview
                     8.3.2 Financial performance
                     8.3.3 Pipeline analysis
                     8.3.4 Strategic initiatives
                 8.4 Avexis, Inc.
                     8.4.1 Company overview
                     8.4.2 Financial performance
                     8.4.3 Pipeline analysis
                     8.4.4 Strategic initiatives
                 8.5 Novartis AG
                     8.5.1 Company overview
                     8.5.2 Financial performance
                     8.5.3 Pipeline analysis
                     8.5.4 Strategic initiatives
                 8.6 Cytokinetics, Inc.
                     8.6.1 Company overview
                     8.6.2 Financial performance
                     8.6.3 Product benchmarking
                     8.6.4 Strategic initiatives



List of Tables

TABLE 1 Pipeline analysis of SMA treatment therapies
TABLE 2 North America spinal muscular atrophy treatment market, by disease type, 2015 - 2026 (USD Million)
TABLE 3 North America spinal muscular atrophy treatment market, by treatment, 2015 - 2026 (USD Million)
TABLE 4 North America spinal muscular atrophy treatment market, by drug, 2015 - 2026 (USD Million)
TABLE 5 North America spinal muscular atrophy treatment market, by route of administration, 2015 - 2026 (USD Million)
TABLE 6 U.S. spinal muscular atrophy treatment market, by disease type, 2015 - 2026 (USD Million)
TABLE 7 U.S. spinal muscular atrophy treatment market, by treatment, 2015 - 2026 (USD Million)
TABLE 8 U.S. spinal muscular atrophy treatment market, by drug, 2015 - 2026 (USD Million)
TABLE 9 U.S. spinal muscular atrophy treatment market, by route of administration, 2015 - 2026 (USD Million)
TABLE 10 Canada spinal muscular atrophy treatment market, by disease type, 2015 - 2026 (USD Million)
TABLE 11 Canada spinal muscular atrophy treatment market, by treatment, 2015 - 2026 (USD Million)
TABLE 12 Canada spinal muscular atrophy treatment market, by drug, 2015 - 2026 (USD Million)
TABLE 13 Canada spinal muscular atrophy treatment market, by route of administration, 2015 - 2026 (USD Million)
TABLE 14 Europe spinal muscular atrophy treatment market, by disease type, 2015 - 2026 (USD Million)
TABLE 15 Europe spinal muscular atrophy treatment market, by treatment, 2015 - 2026 (USD Million)
TABLE 16 Europe spinal muscular atrophy treatment market, by drug, 2015 - 2026 (USD Million)
TABLE 17 Europe spinal muscular atrophy treatment market, by route of administration, 2015 - 2026 (USD Million)
TABLE 18 U.K. spinal muscular atrophy treatment market, by disease type, 2015 - 2026 (USD Million)
TABLE 19 U.K. spinal muscular atrophy treatment market, by treatment, 2015 - 2026 (USD Million)
TABLE 20 U.K. spinal muscular atrophy treatment market, by drug, 2015 - 2026 (USD Million)
TABLE 21 U.K. spinal muscular atrophy treatment market, by route of administration, 2015 - 2026 (USD Million)
TABLE 22 Germany spinal muscular atrophy treatment market, by disease type, 2015 - 2026 (USD Million)
TABLE 23 Germany spinal muscular atrophy treatment market, by treatment, 2015 - 2026 (USD Million)
TABLE 24 Germany spinal muscular atrophy treatment market, by drug, 2015 - 2026 (USD Million)
TABLE 25 Germany spinal muscular atrophy treatment market, by route of administration, 2015 - 2026 (USD Million)
TABLE 26 Asia Pacific spinal muscular atrophy treatment market, by disease type, 2015 - 2026 (USD Million)
TABLE 27 Asia Pacific spinal muscular atrophy treatment market, by treatment, 2015 - 2026 (USD Million)
TABLE 28 Asia Pacific spinal muscular atrophy treatment market, by drug, 2015 - 2026 (USD Million)
TABLE 29 Asia Pacific spinal muscular atrophy treatment market, by route of administration, 2015 - 2026 (USD Million)
TABLE 30 Japan spinal muscular atrophy treatment market, by disease type, 2015 - 2026 (USD Million)
TABLE 31 Japan spinal muscular atrophy treatment market, by treatment, 2015 - 2026 (USD Million)
TABLE 32 Japan spinal muscular atrophy treatment market, by drug, 2015 - 2026 (USD Million)
TABLE 33 Japan spinal muscular atrophy treatment market, by route of administration, 2015 - 2026 (USD Million)
TABLE 34 China spinal muscular atrophy treatment market, by disease type, 2015 - 2026 (USD Million)
TABLE 35 China spinal muscular atrophy treatment market, by treatment, 2015 - 2026 (USD Million)
TABLE 36 China spinal muscular atrophy treatment market, by drug, 2015 - 2026 (USD Million)
TABLE 37 China spinal muscular atrophy treatment market, by route of administration, 2015 - 2026 (USD Million)
TABLE 38 Latin America spinal muscular atrophy treatment market, by disease type, 2015 - 2026 (USD Million)
TABLE 39 Latin America spinal muscular atrophy treatment market, by treatment, 2015 - 2026 (USD Million)
TABLE 40 Latin America spinal muscular atrophy treatment market, by drug, 2015 - 2026 (USD Million)
TABLE 41 Latin America spinal muscular atrophy treatment market, by route of administration, 2015 - 2026 (USD Million)
TABLE 42 Mexico spinal muscular atrophy treatment market, by disease type, 2015 - 2026 (USD Million)
TABLE 43 Mexico spinal muscular atrophy treatment market, by treatment, 2015 - 2026 (USD Million)
TABLE 44 Mexico spinal muscular atrophy treatment market, by drug, 2015 - 2026 (USD Million)
TABLE 45 Mexico spinal muscular atrophy treatment market, by route of administration, 2015 - 2026 (USD Million)
TABLE 46 Brazil spinal muscular atrophy treatment market, by disease type, 2015 - 2026 (USD Million)
TABLE 47 Brazil spinal muscular atrophy treatment market, by treatment, 2015 - 2026 (USD Million)
TABLE 48 Brazil spinal muscular atrophy treatment market, by drug, 2015 - 2026 (USD Million)
TABLE 49 Brazil spinal muscular atrophy treatment market, by route of administration, 2015 - 2026 (USD Million)
TABLE 50 MEA spinal muscular atrophy treatment market, by disease type, 2015 - 2026 (USD Million)
TABLE 51 MEA spinal muscular atrophy treatment market, by treatment, 2015 - 2026 (USD Million)
TABLE 52 MEA spinal muscular atrophy treatment market, by drug, 2015 - 2026 (USD Million)
TABLE 53 MEA spinal muscular atrophy treatment market, by route of administration, 2015 - 2026 (USD Million)
TABLE 54 South Africa spinal muscular atrophy treatment market, by disease type, 2015 - 2026 (USD Million)
TABLE 55 South Africa spinal muscular atrophy treatment market, by treatment, 2015 - 2026 (USD Million)
TABLE 56 South Africa spinal muscular atrophy treatment market, by drug, 2015 - 2026 (USD Million)
TABLE 57 South Africa spinal muscular atrophy treatment market, by route of administration, 2015 - 2026 (USD Million)



List of Figures

FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain-based sizing & forecasting
FIG. 6 QFD modelling for market share assessment
FIG. 7 Market summary 2017, (USD Million)
FIG. 8 Market trends & outlook
FIG. 9 Market segmentation & scope
FIG. 10 Market driver relevance analysis (Current & future impact)
FIG. 11 Number of companies investing for discovering new therapies
FIG. 12 Market restraint relevance analysis (Current & future impact)
FIG. 13 Key Opportunities Prioritized
FIG. 14 SWOT Analysis, By Factor (political & legal, economic, and technological)
FIG. 15 Porter’s Five Forces Analysis
FIG. 16 Spinal muscular atrophy treatment market, disease type outlook: key takeaways (USD Million)
FIG. 17 Spinal muscular atrophy treatment market: Disease type movement analysis (USD Million)
FIG. 18 Type 1 market estimates and forecasts, 2015 - 2026 (USD Million)
FIG. 19 Type 2 market estimates and forecasts, 2015 - 2026 (USD Million)
FIG. 20 Type 3 market estimates and forecasts, 2015 - 2026 (USD Million)
FIG. 21 Type 4 market estimates and forecasts, 2015 - 2026 (USD million)
FIG. 22 Spinal muscular atrophy treatment market, treatment outlook: Key takeaways (USD Million)
FIG. 23 Spinal muscular atrophy treatment market: Treatment movement analysis (USD Million)
FIG. 24 Gene therapy market estimates and forecasts, 2015 - 2026 (USD Million)
FIG. 25 Drug market estimates and forecasts, 2015 - 2026 (USD Million)
FIG. 26 Spinraza market estimates and forecasts, 2015 - 2026 (USD Million)
FIG. 27 RG6083 (Olesoxime) market estimates and forecasts, 2015 - 2026 (USD Million)
FIG. 28 RG7916 market estimates and forecasts, 2015 - 2026 (USD Million)
FIG. 29 Spinal muscular atrophy treatment market, route of administration outlook: Key takeaways (USD Million)
FIG. 30 Spinal muscular atrophy treatment market: Route of administration movement analysis (USD Million)
FIG. 31 Oral market estimates and forecasts, 2015 - 2026 (USD Million)
FIG. 32 Intrathecal market estimates and forecasts, 2015 - 2026 (USD Million)
FIG. 33 Regional market place: Key takeaways (USD Million)
FIG. 34 Spinal muscular atrophy treatment market: Regional movement analysis (USD Million)
FIG. 35 North America spinal muscular atrophy treatment market estimates and forecasts, 2015 - 2026 (USD Million)
FIG. 36 U.S. spinal muscular atrophy treatment market estimates and forecasts, 2015 - 2026 (USD Million)
FIG. 37 Canada spinal muscular atrophy treatment market estimates and forecasts, 2015 - 2026 (USD Million)
FIG. 38 Europe spinal muscular atrophy treatment market estimates and forecasts, 2015 - 2026 (USD Million)
FIG. 39 U.K. spinal muscular atrophy treatment market estimates and forecasts, 2015 - 2026 (USD Million)
FIG. 40 Germany spinal muscular atrophy treatment market estimates and forecasts, 2015 - 2026 (USD Million)
FIG. 41 Asia Pacific spinal muscular atrophy treatment market estimates and forecasts, 2015 - 2026 (USD Million)
FIG. 42 Japan spinal muscular atrophy treatment market estimates and forecasts, 2015 - 2026 (USD Million)
FIG. 43 China spinal muscular atrophy treatment market estimates and forecasts, 2015 - 2026 (USD Million)
FIG. 44 Latin America spinal muscular atrophy treatment market estimates and forecasts, 2015 - 2026 (USD Million)
FIG. 45 Mexico spinal muscular atrophy treatment market estimates and forecasts, 2015 - 2026 (USD Million)
FIG. 46 Brazil spinal muscular atrophy treatment market estimates and forecasts, 2015 - 2026 (USD Million)
FIG. 47 MEA spinal muscular atrophy treatment market estimates and forecasts, 2015 - 2026 (USD Million)
FIG. 48 South Africa spinal muscular atrophy treatment market estimates and forecasts, 2015 - 2026 (USD Million)

 

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers
Ask to Expert